DexCom
DXCM
Collegium Pharmaceutical
COLL
Lantheus
LNTH
Cars.com
CARS
YETI Holdings
YETI
US Stock MarketDetailed Quotes
ELTX Elicio Therapeutics
- 5.620
- +0.480+9.34%
Close Jan 3 16:00 ET
60.65MMarket Cap-1.29P/E (TTM)
5.657High5.140Low48.26KVolume5.430Open5.140Pre Close261.16KTurnover0.57%Turnover RatioLossP/E (Static)10.79MShares11.45052wk High-3.19P/B47.27MFloat Cap2.96052wk Low--Dividend TTM8.41MShs Float263.000Historical High--Div YieldTTM10.06%Amplitude2.960Historical Low5.411Avg Price1Lot Size
About Elicio Therapeutics Company
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of cancer immunotherapies. It focuses on its Amphiphile platform for trafficking lymph nodes. The company was founded by Darrell Irvine in August 2011 and is headquartered in Boston, MA.
Company Profile
SymbolELTX
Company NameElicio Therapeutics
Listing DateFeb 5, 2021
Founded2011
CEOMr. Robert Connelly
MarketNASDAQ
Employees32
Fiscal Year Ends12-31
Address451 D Street,5th floor, Suite 501
CityBoston
ProvinceMassachusetts
CountryUnited States of America
Zip Code02210
Phone1-857-209-0050
Websitehttp://www.elicio.com
Company Executives
- Name
- Position
- Salary
- Robert Connelly
- Chief Executive Officer, President, Director, Principal Accounting Officer and Principal Financial Officer
- 678.30K
- Dr. Christopher Haqq, M.D.,PhD
- Executive Vice President, Head of Research and Development and Chief Medical Officer
- 673.82K
- Dr. Peter DeMuth, PhD
- Chief Scientific Officer
- --
- Dr. Julian Ada PhD
- Chairman of the Board
- 96.05K
- Yekaterina Chudnovsky
- Director
- 48.68K
- Dr. Jay R. Venkatesan, M.D.
- Director
- 45.76K
- Karen J. Wilson
- Independent Director
- 101.02K
- Dr. Robert R. Ruffolo, Jr, Ph.D
- Independent Director
- 63.26K
- Carol Gail Ashe
- Independent Director
- 71.59K
- Dr. Allen R. Nissenson,M.D.
- Independent Director
- 91.22K